A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Romosozumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors UCB Biopharma
- 24 Nov 2023 Status changed from active, no longer recruiting to completed.
- 22 Dec 2022 Planned End Date changed from 5 Dec 2023 to 10 Nov 2023.
- 22 Dec 2022 Planned primary completion date changed from 5 Dec 2023 to 10 Nov 2023.